Ventilator-associated tracheobronchitis: pre-emptive, appropriate antibiotic therapy recommended

Donald E Craven, Jana Hudcova, Yuxiu Lei, Donald E Craven, Jana Hudcova, Yuxiu Lei

Abstract

Nseir and colleagues presented data from a large multicenter study of patients with ventilator-associated tracheobronchitis (VAT), demonstrating that appropriate antibiotic therapy for VAT was an independent predictor for reducing transition to pneumonia (ventilator-associated pneumonia, or VAP). These data added to the growing evidence supporting the use of appropriate antibiotic therapy for VAT as a standard of care to prevent VAP and improve patient outcomes.

Figures

Figure 1
Figure 1
Pathogenesis and routine antibiotic therapy for urinary tract infections versus ventilator-associated pneumonia and tracheobronchitis. (A) The pathogenesis of ‘ascending’ urinary tract infection due to cystitis or pyelonephritis or both, which are currently treated with antibiotics as a ‘standard of care’. (B) The pathogenesis of ‘descending’, primarily ‘one-way’ respiratory tract infection manifests as ventilator-associated tracheobronchitis or pneumonia, for which we would recommend treatment with intravenous or aerosolized antibiotic therapy or both. Reprinted with permission from Lippincott Williams & Wilkins [12].

References

    1. Nseir S, Martin-Loeches I, Makris D, Jaillette E, Karvouniaris M, Valles J, Zakynthinos E, Artigas A. Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia. Crit Care. 2014;18:R129. doi: 10.1186/cc13940.
    1. Nseir S, Di Pompeo C, Pronnier P, Beague S, Onimus T, Saulnier F, Grandbastien B, Mathieu D, Delvallez-Roussel M, Durocher A. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J. 2002;20:1483–1489. doi: 10.1183/09031936.02.00012902.
    1. Nseir S, Favory R, Jozefowicz E, Decamps F, Dewavrin F, Brunin G, Di Pompeo C, Mathieu D, Durocher A, VAT Study Group Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study. Crit Care. 2008;12:R62. doi: 10.1186/cc6890.
    1. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, Varela M, Tempone AK, O’Riordan T, Daroowalla F, Richman P. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med. 2008;36:2008–2013. doi: 10.1097/CCM.0b013e31817c0f9e.
    1. Craven DE, Lei Y, Ruthazer R, Sarwar A, Hudcova J. Incidence and outcomes of ventilator-associated tracheobronchitis and pneumonia. Am J Med. 2013;126:542–549. doi: 10.1016/j.amjmed.2012.12.012.
    1. Agrafiotis M, Siempos II, Falagas ME. Frequency, prevention, outcome and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Respir Med. 2010;104:325–336. doi: 10.1016/j.rmed.2009.09.001.
    1. Dallas J, Skrupky L, Abebe N, Boyle WA, 3rd, Kollef MH. Ventilator-associated tracheobronchitis in a mixed surgical and medical ICU population. Chest. 2011;139:513–518. doi: 10.1378/chest.10-1336.
    1. Bouza E, Granda MJ, Hortal J, Barrio JM, Cercenado E, Muñoz P. Pre-emptive broad-spectrum treatment for ventilator-associated pneumonia in high-risk patients. Intensive Care Med. 2013;39:1547–1555. doi: 10.1007/s00134-013-2997-6.
    1. Kollef MH, Hamilton CW, Montgomery AB. Aerosolized antibiotics: do they add to the treatment of pneumonia? Curr Opin Infect Dis. 2013;26:538–544. doi: 10.1097/QCO.0000000000000004.
    1. Abu-Salah T, Dhand R. Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update. Adv Ther. 2011;28:728–747. doi: 10.1007/s12325-011-0051-z.
    1. Montgomery AB, Vallance S, Abuan T, Tservistas M, Davies A: A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI Investigational eFlow Inline Nebulizer System in mechanically ventilated patients.J Aerosol Med Pulm Drug Deliv 2014, Epub ahead of print.
    1. Craven DE, Hudcova J, Craven KA, Scopa C, Lei Y: Antibiotic treatment of ventilator-associated tracheobronchitis: to treat or not to treat?Curr Opin Crit Care 2014, Epub ahead of print.
    1. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, Brummel NE, Hughes CG, Vasilevskis EE, Shintani AK, Moons KG, Geevarghese SK, Canonico A, Hopkins RO, Bernard GR, Dittus RS, Ely EW, BRAIN-ICU Study Investigators Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369:1306–1316. doi: 10.1056/NEJMoa1301372.
    1. Herridge M, Cameron JI. Disability after critical illness. N Engl J Med. 2013;369:1367–1369. doi: 10.1056/NEJMe1309482.
    1. Unroe M, Kahn JM, Carson SS, Govert JA, Martinu T, Sathy SJ, Clay AS, Chia J, Gray A, Tulsky JA, Cox CE. One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: a cohort study. Ann Intern Med. 2010;153:167–175. doi: 10.7326/0003-4819-153-3-201008030-00007.
    1. Rodríguez A, Póvoa P, Nseir S, Salluh J, Curcio D, Martín-Loeches I, TAVeM group investigators Incidence and diagnosis of ventilator-associated tracheobronchitis (VAT) in the intensive care unit: an international online survey. Crit Care. 2014;18:R32. doi: 10.1186/cc13725.
    1. Craven DE, Hjalmarson KI. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. Clin Infect Dis. 2010;51(Suppl 1):S59–S66. doi: 10.1086/653051.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir